Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(0.79)
# 3,694
Out of 4,783 analysts
301
Total ratings
23.08%
Success rate
-29.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACRV Acrivon Therapeutics | Reiterates: Buy | $19 | $2.52 | +653.97% | 12 | Mar 28, 2025 | |
| NKTX Nkarta | Reiterates: Buy | $18 | $1.97 | +813.71% | 15 | Mar 27, 2025 | |
| IMNN Imunon | Reiterates: Buy | $14 | $1.14 | +1,128.07% | 12 | Mar 26, 2025 | |
| ATOS Atossa Therapeutics | Reiterates: Buy | $7 | $0.70 | +902.00% | 14 | Mar 26, 2025 | |
| GNLX Genelux | Reiterates: Buy | $30 | $3.03 | +890.10% | 6 | Mar 25, 2025 | |
| CNTX Context Therapeutics | Reiterates: Buy | $5 | $0.74 | +578.89% | 11 | Mar 21, 2025 | |
| FEMY Femasys | Maintains: Buy | $12 → $15 | $1.34 | +1,023.60% | 20 | Mar 19, 2025 | |
| OLMA Olema Pharmaceuticals | Reiterates: Buy | $30 | $4.20 | +614.29% | 19 | Mar 19, 2025 | |
| INKT MiNK Therapeutics | Reiterates: Buy | $35 | $9.23 | +279.40% | 12 | Mar 18, 2025 | |
| AGEN Agenus | Reiterates: Neutral | n/a | $1.66 | - | 15 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $11 | $1.85 | +496.21% | 10 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $3 | $0.53 | +465.29% | 8 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 | $0.52 | +3,746.15% | 16 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.65 | - | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $4.84 | +726.45% | 9 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $1.16 | +934.48% | 12 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $22 | $18.65 | +17.96% | 8 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $24 | $8.49 | +182.69% | 5 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $58 | $30.84 | +88.07% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $0.69 | +2,501.91% | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $32 | $4.04 | +692.08% | 13 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.23 | - | 15 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $18.97 | +100.32% | 18 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $6 | $2.64 | +127.27% | 13 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $115 | $68.51 | +67.86% | 12 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $2.76 | +1,097.74% | 14 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $0.76 | +952.63% | 4 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $3.72 | - | 1 | Apr 25, 2024 |
Acrivon Therapeutics
Mar 28, 2025
Reiterates: Buy
Price Target: $19
Current: $2.52
Upside: +653.97%
Nkarta
Mar 27, 2025
Reiterates: Buy
Price Target: $18
Current: $1.97
Upside: +813.71%
Imunon
Mar 26, 2025
Reiterates: Buy
Price Target: $14
Current: $1.14
Upside: +1,128.07%
Atossa Therapeutics
Mar 26, 2025
Reiterates: Buy
Price Target: $7
Current: $0.70
Upside: +902.00%
Genelux
Mar 25, 2025
Reiterates: Buy
Price Target: $30
Current: $3.03
Upside: +890.10%
Context Therapeutics
Mar 21, 2025
Reiterates: Buy
Price Target: $5
Current: $0.74
Upside: +578.89%
Femasys
Mar 19, 2025
Maintains: Buy
Price Target: $12 → $15
Current: $1.34
Upside: +1,023.60%
Olema Pharmaceuticals
Mar 19, 2025
Reiterates: Buy
Price Target: $30
Current: $4.20
Upside: +614.29%
MiNK Therapeutics
Mar 18, 2025
Reiterates: Buy
Price Target: $35
Current: $9.23
Upside: +279.40%
Agenus
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.66
Upside: -
Mar 18, 2025
Reiterates: Buy
Price Target: $11
Current: $1.85
Upside: +496.21%
Mar 17, 2025
Reiterates: Buy
Price Target: $3
Current: $0.53
Upside: +465.29%
Mar 13, 2025
Reiterates: Buy
Price Target: $20
Current: $0.52
Upside: +3,746.15%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.65
Upside: -
Mar 11, 2025
Reiterates: Buy
Price Target: $40
Current: $4.84
Upside: +726.45%
Mar 5, 2025
Reiterates: Buy
Price Target: $12
Current: $1.16
Upside: +934.48%
Mar 4, 2025
Reiterates: Neutral
Price Target: $22
Current: $18.65
Upside: +17.96%
Feb 26, 2025
Upgrades: Buy
Price Target: $24
Current: $8.49
Upside: +182.69%
Feb 24, 2025
Reiterates: Buy
Price Target: $58
Current: $30.84
Upside: +88.07%
Feb 3, 2025
Reiterates: Buy
Price Target: $18
Current: $0.69
Upside: +2,501.91%
Feb 3, 2025
Maintains: Buy
Price Target: $15 → $32
Current: $4.04
Upside: +692.08%
Jan 14, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.23
Upside: -
Jan 14, 2025
Reiterates: Buy
Price Target: $38
Current: $18.97
Upside: +100.32%
Jan 7, 2025
Maintains: Neutral
Price Target: $8 → $6
Current: $2.64
Upside: +127.27%
Dec 10, 2024
Reiterates: Buy
Price Target: $115
Current: $68.51
Upside: +67.86%
Nov 15, 2024
Reiterates: Buy
Price Target: $33
Current: $2.76
Upside: +1,097.74%
Sep 6, 2024
Reiterates: Buy
Price Target: $8
Current: $0.76
Upside: +952.63%
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.72
Upside: -